**b**|**e**|**i** resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

#### Acinetobacter baumannii, Strain MRSN 7725

#### Catalog No. NR-52182

This reagent is the tangible property of the U.S. Government.

#### **Product Description:**

Acinetobacter baumannii (A. baumannii), strain MRSN 7725 was isolated in 2006 from a human wound sample in the United States as part of a global surveillance program. NR-52182 was deposited as multi-locus sequence type (MLST) ST 412, resistant to trimethoprim/sulfamethoxazole, sensitive to amikacin, cefepime, ceftazidime, ceftriaxone, ciprofloxacin, colistin, gentamicin, imipenem, levofloxacin, meropenem, tetracycline and tobramycin and intermediately resistant to ampicillin/sulbactam. NR-52182 was produced by inoculation of the deposited material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

# Lot: 70041739

# Manufacturing Date: 05FEB2021

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: <u>Contact@BEIResources.org</u>. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Circular, convex, entire, smooth and cream (Figure 1)
Growth at 44°C ± 2°C <sup>1</sup> 1 day in an aerobic atmosphere on Tryptic Soy agar	Growth	Growth
Motility BBL™ Motility Test Medium w/TTC Indicator for 1 day at 35°C in an aerobic atmosphere	Report results	Motile
VITEK <sup>®</sup> MS (MALDI-TOF)	A. baumannii	A. baumannii (99.9%)
Antibiotic Susceptibility Profile <sup>2,3</sup>		
Amikacin	Sensitive	Sensitive (4 µg/mL)
Ampicillin/sulbactam	Intermediate	Sensitive (3 to 4 µg/mL) <sup>4</sup>
Cefepime	Sensitive	Sensitive (1.5 µg/mL)
Ceftriaxone	Sensitive	Intermediate (16 µg/mL) <sup>5</sup>
Ceftazidime	Sensitive	Sensitive (4 µg/mL)
Ciprofloxacin	Sensitive	Sensitive (1 µg/mL)
Colistin	Sensitive	Sensitive (≤ 0.25 µg/mL)
Gentamicin	Sensitive	Sensitive (≤ 1 µg/mL)
Imipenem	Sensitive	Sensitive (≤ 1 µg/mL)
Levofloxacin	Sensitive	Sensitive (≤ 1 µg/mL)
Meropenem	Sensitive	Sensitive (≤ 1 µg/mL)
Trimethoprim/sulfamethoxazole	Resistant	Resistant (> 4 µg/mL)
Tobramycin	Sensitive	Sensitive (≤ 1 µg/mL)
Tetracycline	Sensitive	Sensitive (1 µg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1470 base pairs)	≥ 99% sequence identity to <i>A. baumannii</i> , strain MRSN 7725 (GenBank: VHDW01000073.1)	99.9% sequence identity to <i>A. baumannii</i> , strain MRSN 7725 (GenBank: VHDW01000073.1)
Purity	Growth consistent with expected	Growth consistent with expected
7 days at 37°C in an aerobic atmosphere with and without 5% CO <sub>2</sub> on Tryptic Soy agar	colony morphology	colony morphology

BEI Resources www.beiresources.org E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898

# biei resources

# **Certificate of Analysis for NR-52182**

SUPPORTING INFECTIOUS DISEASE RESEARCH

TEST	SPECIFICATIONS	RESULTS
Viability	Growth	Growth

<sup>1</sup>Growth at 44°C differentiates A. baumannii from A. calcoaceticus and A. pittii, which do not grow at 44°C.


<sup>2</sup>Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

<sup>3</sup>Antibiotic susceptibility was tested using a combination of VITEK<sup>®</sup>2 GN82, Sensititre GNX2F AST and E-test strips.

<sup>4</sup>A. baumannii, strain MRSN 7725 was deposited as intermediately resistant to ampicillin/sulbactam but showed a MIC of 3 to 4 μg per mL (interpreted as sensitive) for ampicillin/sulbactam during QC testing. Testing was performed in quadruplicate.

<sup>5</sup>The susceptibility result for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.

#### Figure 1: Colony Morphology



# /Heather Couch/ Heather Couch

31 AUG 2021

Program Manager or designee, ATCC Federal Solutions

ATCC<sup>®</sup>, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC<sup>®</sup>'s knowledge.

ATCC<sup>®</sup> is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use.

